Opportunity
Saskatchewan Tenders #ACAN-200110926
Saskatchewan Health Authority seeks Boston Scientific Rezum therapy system and support for BPH treatment
Posted
November 16, 2026
Respond By
December 11, 2026
Identifier
ACAN-200110926
NAICS
423450
The Saskatchewan Health Authority plans a three-year supply of a Rezum system to treat benign prostatic hyperplasia (BPH). - Government buyer: Saskatchewan Health Authority (SHA), Provincial Procurement Contracts Operations South. - Intended supplier and named OEM: BOSTON SCIENTIFIC LIMITED. - Products requested: Rezum water-vapor therapy system, including a generator with vapor-generation and thermal-dose controls, a closed integrated generator-delivery platform, and compatible single-use Rezum Delivery Device Kits with vapor-emitter needles. Quantities and part numbers are not specified. - Services and support: Associated software, accessories, consumables, installation, training, calibration, maintenance, updates, technical support, and repairs; the supplier must also maintain an uninterrupted Canadian supply of single-use devices and consumables. - Notable requirements: The system must be authorized for sale and clinical use in Canada for the proposed indication, support outpatient or ambulatory treatment, and have clinical evidence addressing safety, symptom improvement, durability, and preservation of sexual function. Applicable medical-device, electrical-safety, infection-control, and reprocessing requirements apply. - Competition: SHA identifies Boston Scientific as the intended supplier and states that it knows of no equivalent alternatives. Other suppliers may submit capability information; SHA may conduct a further competition if it identifies qualified alternatives.
Description
The Saskatchewan Health Authority intends to award a three-year contract for a Rezum Water Vapour Therapy System to BOSTON SCIENTIFIC LIMITED. The system includes a generator, single-use delivery device kits, and a closed generator-delivery platform, with software, service, calibration, and training supported by the vendor. The therapy is for transurethral treatment of obstructive prostate tissue associated with benign prostatic hyperplasia. Other suppliers may submit statements of capabilities during the 25-calendar-day posting period to demonstrate they can meet the stated requirements; if qualified suppliers are identified, SHA may conduct a further competitive process.